Market Analysis
ImmunityBio Surges as Anktiva Drives 671% Revenue Growth
IBRX extended its rally after the company posted explosive 671% revenue growth, fueled by rising demand for its bladder cancer drug, Anktiva.
Total Stories
6
News
IBRX
Section
IBRX
Market Analysis
Why Is ImmunityBio (IBRX) Stock Jumping Today? ANKTIVA Gains NCCN Backing
ImmunityBio (IBRX) stock jumped over 6% in premarket trading after the NCCN added ANKTIVA to its bladder cancer guidelines, expanding its use.
Market Analysis
Why Is ImmunityBio (IBRX) Rallying Today? EU Approves Anktiva
ImmunityBio stock surged more than 20% after the European Commission granted conditional approval for its bladder cancer treatment, Anktiva.
Market Analysis
Why Are IBRX Shares Up in Premarket? FDA Feedback Boosts ANKTIVA
ImmunityBio shares jumped in premarket trading after the FDA outlined next steps for expanding ANKTIVA’s bladder cancer label.
Market Analysis
Why Is ImmunityBio (IBRX) Stock Up Premarket? ANKTIVA Sales Jump 700%
ImmunityBio stock jumped after the company reported preliminary 2025 net product revenue of $113 million, up about 700% year over year.
Earnings
Amid Biotech Pitfalls, this Stock Has Outperformed NVDA in the Last 3 Months
In the last three months, this biotech stock outperformed Nvidia (NVDA) by over 3x.